Quidel Reports 2008 Results
Full Year 2008 & Recent Highlights: Global revenues were $128 million, an 8.5% increase year over year Domestic revenues grew 7% to $109 million International revenues grew 19%
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m.
The FDA has previously approved this improved formulation of Epoprostenol for Injection (1.5mg/ml vial) for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with
The multi-dose, placebo-controlled, three-period cross-over study, included 20 stable asthmatic patients. LAS 100977 demonstrated 24 hour bronchodilation and sustained efficacy during multiple dose administrations with no significant increase